- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Academy of Managed Care Pharmacy: Specialty drug approvals trend upward; biobetters gain momentum
Within the next 5 years, approximately $100 billion will be lost on previous blockbuster brands that will lose patent protection.
Key Points
Within the next 5 years approximately $100 billion will be lost on previous blockbuster brands that will lose (or lost) patent protection. For manufacturers to enhance their return on investment, they are refocusing on researching and marketing specialty drugs, according to a specialty pharmaceuticals pipeline update at the Academy of Managed Care Pharmacy's 23rd Annual Meeting and Showcase, Minneapolis.
There is an upward trend of specialty drug approvals, including those that are shifting for use as the mainstays of treatment. In the last 3 years, specialty approvals have increased from 8 in 2008 to 17 in 2010. From 2012 and beyond, approvals are expected to increase while some large pharmaceutical manufacturers have begun to partner or purchase biotech companies to enhance their product pipelines.
Other trends include research and approval of oral specialty agents with new mechanisms of action for the management of rheumatoid arthritis (RA), multiple sclerosis (MS), and hepatitis C virus (HCV) infection. There also will be more oral options for patients with moderate-to-severe and refractory disease, such as tofacitinib (RA); BG-12 or laquinimod (MS); and telaprevir or boceprevir (HCV) genotype 1. There also is a focus on creating biosimilars or "biobetters," which are modifications of biotechnology products such as better dosing, improved administration (such as from intravenous infusion to subcutaneous administration; pegylating products for every 2-week/4-week administration vs weekly administration), or more targeted therapies.
For more, go to http://formularyjournal.modernmedicine.com/specialtydrugs.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
